Literature DB >> 29915443

Fecal calprotectin reflects endoscopic activity in patients with small-bowel Crohn's disease according to double-balloon endoscopy findings.

Rinzaburo Matsuura1, Osamu Watanabe1, Masanao Nakamura1, Takeshi Yamamura2, Masanobu Matsushita1, Hiroki Suhara1, Kazuhiro Furukawa2, Takuya Ishikawa1, Kohei Funasaka1, Eizaburo Ohno1, Hiroki Kawashima1, Ryoji Miyahara1, Yoshiki Hirooka2, Hidemi Goto1.   

Abstract

Fecal calprotectin (FC) has drawn attention as a biomarker in the evaluation of Crohn's disease (CD). However, few reports have provided a detailed examination of the relationship between small-bowel CD lesions and FC levels. The present study aimed to examine the entire small bowel using double-balloon endoscopy (DBE) and to determine the relationship between the endoscopic activity in small-bowel CD and FC levels. Twenty small-bowel CD patients, who underwent DBE, were prospectively enrolled. Endoscopic evaluation was based on the simple endoscopic score for CD, with the small bowel divided into four regions. This score was defined as the double-balloon endoscopic score for CD (DES-CD). Furthermore, to focus on mucosal membrane damage, we used the partial DES-CD (pDES-CD), in which presence of stenosis was excluded from DES-CD. DES-CD revealed a correlation with FC (γ = 0.691, P = 0.001) and C-reactive protein (CRP) (γ = 0.631, P = 0.003) levels. Furthermore, pDES-CD showed a correlation with the FC level (γ = 0.747, P < 0.001), erythrocyte sedimentation rate (γ = 0.492, P = 0.028), and the CRP level (γ = 0.605, P = 0.005). CD Activity Index and endoscopic score showed no correlation. Our results revealed a correlation between the endoscopic activity in small-bowel CD and FC levels. Furthermore, pDES-CD showed a strong correlation with FC levels. This may be because FC levels were elevated due to mucosal membrane damages, rather than stenoses.

Entities:  

Keywords:  Crohn’s disease; double-balloon endoscopy; fecal calprotectin

Year:  2018        PMID: 29915443      PMCID: PMC5995737          DOI: 10.18999/nagjms.80.2.257

Source DB:  PubMed          Journal:  Nagoya J Med Sci        ISSN: 0027-7622            Impact factor:   1.131


  29 in total

1.  Small bowel involvement in Crohn's disease: a prospective comparison of wireless capsule endoscopy and computed tomography enteroclysis.

Authors:  W A Voderholzer; J Beinhoelzl; P Rogalla; S Murrer; G Schachschal; H Lochs; M-A Ortner
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

Review 2.  Update of fecal markers of inflammation in inflammatory bowel disease.

Authors:  Thomas A Judd; Andrew S Day; Daniel A Lemberg; Dan Turner; Steven T Leach
Journal:  J Gastroenterol Hepatol       Date:  2011-10       Impact factor: 4.029

3.  Fecal Immunochemical Test Versus Fecal Calprotectin for Prediction of Mucosal Healing in Crohn's Disease.

Authors:  Toshihiro Inokuchi; Jun Kato; Sakiko Hiraoka; Shiho Takashima; Asuka Nakarai; Daisuke Takei; Yuusaku Sugihara; Masahiro Takahara; Seiji Kawano; Keita Harada; Hiroyuki Okada
Journal:  Inflamm Bowel Dis       Date:  2016-05       Impact factor: 5.325

4.  Correlation of the Endoscopic and Magnetic Resonance Scoring Systems in the Deep Small Intestine in Crohn's Disease.

Authors:  Kento Takenaka; Kazuo Ohtsuka; Yoshio Kitazume; Masakazu Nagahori; Toshimitsu Fujii; Eiko Saito; Tomoyuki Fujioka; Katsuyoshi Matsuoka; Makoto Naganuma; Mamoru Watanabe
Journal:  Inflamm Bowel Dis       Date:  2015-08       Impact factor: 5.325

5.  Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI.

Authors:  Alain M Schoepfer; Christoph Beglinger; Alex Straumann; Michael Trummler; Stephan R Vavricka; Lukas E Bruegger; Frank Seibold
Journal:  Am J Gastroenterol       Date:  2009-09-15       Impact factor: 10.864

Review 6.  Monitoring disease activity by stool analyses: from occult blood to molecular markers of intestinal inflammation and damage.

Authors:  D Foell; H Wittkowski; J Roth
Journal:  Gut       Date:  2009-01-09       Impact factor: 23.059

7.  Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease.

Authors:  Fabian Schnitzler; Herma Fidder; Marc Ferrante; Maja Noman; Ingrid Arijs; Gert Van Assche; Ilse Hoffman; Kristel Van Steen; Séverine Vermeire; Paul Rutgeerts
Journal:  Inflamm Bowel Dis       Date:  2009-09       Impact factor: 5.325

8.  Fecal Calprotectin in Ileal Crohn's Disease: Relationship with Magnetic Resonance Enterography and a Pathology Score.

Authors:  Elena Cerrillo; Belén Beltrán; Salvador Pous; Ana Echarri; Jose Carlos Gallego; Marisa Iborra; Jose Pamies; Pilar Nos
Journal:  Inflamm Bowel Dis       Date:  2015-07       Impact factor: 5.325

Review 9.  Laboratory markers in IBD: useful, magic, or unnecessary toys?

Authors:  S Vermeire; G Van Assche; P Rutgeerts
Journal:  Gut       Date:  2006-03       Impact factor: 23.059

Review 10.  Measuring disease activity in Crohn's disease: what is currently available to the clinician.

Authors:  Renata D'Incà; Roberta Caccaro
Journal:  Clin Exp Gastroenterol       Date:  2014-05-20
View more
  2 in total

1.  Fecal calprotectin predicts endoscopic activity and mucosal healing of small bowel Crohn's disease evaluated by double-balloon endoscopy.

Authors:  Wei Han; Juan Wu; Peipei Zhang; Naizhong Hu; Qiao Mei; Jing Hu
Journal:  Int J Colorectal Dis       Date:  2022-08-04       Impact factor: 2.796

2.  Diagnostic yield of colon capsule endoscopy for Crohn's disease lesions in the whole gastrointestinal tract.

Authors:  Keisaku Yamada; Masanao Nakamura; Takeshi Yamamura; Keiko Maeda; Tsunaki Sawada; Yasuyuki Mizutani; Eri Ishikawa; Takuya Ishikawa; Naomi Kakushima; Kazuhiro Furukawa; Eizaburo Ohno; Hiroki Kawashima; Takashi Honda; Masatoshi Ishigami; Mitsuhiro Fujishiro
Journal:  BMC Gastroenterol       Date:  2021-02-16       Impact factor: 3.067

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.